Kolmar BioTech

At a glance

Kolmar BioTech filed 47 disclosures in the last 12 months, including 3 insider, 3 5% holder, 1 issuance and 1 m&a. The most recent key filing was on Jul 20.

Revenue for 2025 was ₩37.6B, down 13% on 2024. It made an operating loss of ₩3.9B. Debt was 271% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩22B and operating profit of ₩409.8M.

The 2025 annual report lists 127 employees with an average tenure of 4.3 years and average pay of ₩50M, #1727 of 2,191 listed companies by average pay. Its 8 directors and auditors were paid ₩69M each on average. It paid no cash dividend for 2025. 천희정 and related parties held 33.61% at year end.

Of 3 recent 5%+ holder reports, 1 raised and 0 cut a stake; the largest stake reported was 64.73% on Apr 3.

From the 2025 annual report

Staff: 127 (74 men, 53 women), of whom 8 on fixed-term contracts. Total pay for the year: ₩6B. Directors and auditors: 8, paid ₩551.8M in total.

No cash dividend was paid for 2025.

Largest shareholder

천희정 holds 12.81%; with 9 related parties the group holds 33.61% of common shares at year end.

Individuals paid ₩500M or more

Auditor: 정진세림회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports